Ascension Health and Wilson, Sonsini, Goodrich & Rosati contributed to the oncology therapy developer's series A round, which was led by Menlo Ventures.
Cofactor Genomics, a US-based startup developing precision medicine treatments for cancer, closed an oversubscribed $18m series A round yesterday featuring healthcare provider Ascension Health and legal firm Wilson, Sonsini, Goodrich & Rosati.
Venture capital firm Menlo Ventures led the round, which included health insurance provider iSelect, VC fund Data Collective, accelerator Y Combinator and Stanford University, while Ascension participated through its strategic investment unit, Ascension Ventures.
Cofactor Genomics is developing precision cancer treatments based on information from RNA, the nuclear…
